A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
CONCLUSIONS: Preoperative D+/-T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.PMID:38457288 | DOI:10.1158/1078-0432.CCR-23-3249 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 8, 2024 Category: Cancer & Oncology Authors: Chang Gon Kim Min Hee Hong Dahee Kim Brian Hyohyoung Lee Hyunwook Kim Chan-Young Ock Geoffrey Kelly Yoon Ji Bang Gamin Kim Jung Eun Lee Chaeyeon Kim Se-Heon Kim Hyun Jun Hong Young Min Park Nam Suk Sim Heejung Park Jin Woo Park Chang Geol Lee Kyung Hwan K Source Type: research
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
CONCLUSIONS: Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.PMID:38456660 | DOI:10.1158/1078-0432.CCR-23-3135 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 8, 2024 Category: Cancer & Oncology Authors: Ryan B Corcoran Khanh T Do Jeong E Kim James M Cleary Aparna R Parikh Oladapo O Yeku Niya Xiong Colin D Weekes Jennifer Veneris Leanne G Ahronian Gianluca Mauri Jun Tian Bryanna L Norden Alexa G Michel Emily E Van Seventer Giulia Siravegna Kyle Camphausen Source Type: research
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
CONCLUSIONS: Preoperative D+/-T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.PMID:38457288 | DOI:10.1158/1078-0432.CCR-23-3249 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 8, 2024 Category: Cancer & Oncology Authors: Chang Gon Kim Min Hee Hong Dahee Kim Brian Hyohyoung Lee Hyunwook Kim Chan-Young Ock Geoffrey Kelly Yoon Ji Bang Gamin Kim Jung Eun Lee Chaeyeon Kim Se-Heon Kim Hyun Jun Hong Young Min Park Nam Suk Sim Heejung Park Jin Woo Park Chang Geol Lee Kyung Hwan K Source Type: research
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
CONCLUSIONS: Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.PMID:38456660 | DOI:10.1158/1078-0432.CCR-23-3135 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 8, 2024 Category: Cancer & Oncology Authors: Ryan B Corcoran Khanh T Do Jeong E Kim James M Cleary Aparna R Parikh Oladapo O Yeku Niya Xiong Colin D Weekes Jennifer Veneris Leanne G Ahronian Gianluca Mauri Jun Tian Bryanna L Norden Alexa G Michel Emily E Van Seventer Giulia Siravegna Kyle Camphausen Source Type: research
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
CONCLUSIONS: Preoperative D+/-T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.PMID:38457288 | DOI:10.1158/1078-0432.CCR-23-3249 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 8, 2024 Category: Cancer & Oncology Authors: Chang Gon Kim Min Hee Hong Dahee Kim Brian Hyohyoung Lee Hyunwook Kim Chan-Young Ock Geoffrey Kelly Yoon Ji Bang Gamin Kim Jung Eun Lee Chaeyeon Kim Se-Heon Kim Hyun Jun Hong Young Min Park Nam Suk Sim Heejung Park Jin Woo Park Chang Geol Lee Kyung Hwan K Source Type: research
Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia
CONCLUSIONS: These results highlight TIM-4-L as a highly prevalent target on AML across a range of genetic classifications and novel target for T cell-based therapy in AML. Further investigations into the role of TIM-4-L in AML pathogenesis and its potential as an anti-leukemic target for clinical development are warranted.PMID:38451195 | DOI:10.1158/1078-0432.CCR-23-3044 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 7, 2024 Category: Cancer & Oncology Authors: Brandon Cieniewicz Edson Oliveira Mike Saxton Damoun Torabi Ankit Bhatta Phanidhar Kukutla Alexander Arballo Zhuo Yang Bi Yu Maria Fate Hongxiu Ning Lawrence Corey Abhishek Maiti Daniel Corey Source Type: research
Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia
CONCLUSIONS: Our study demonstrates a compelling rationale for translating CCL2/CCR2 axis inhibitors in combination with MEK pathway-targeting therapies, as a potent strategy for combating drug resistance in AML. This approach has the potential to enhance the efficacy of treatments to improve AML patient outcomes.PMID:38451486 | DOI:10.1158/1078-0432.CCR-23-2654 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 7, 2024 Category: Cancer & Oncology Authors: Rucha V Modak Katia G de Oliveira Rebola John McClatchy Mona Mohammadhosseini Alisa Damnernsawad Stephen E Kurtz Christopher A Eide Guanming Wu Ted Laderas Tamilla Nechiporuk Marina A Gritsenko Joshua R Hansen Chelsea Hutchinson Sara J C Gosline Paul Pieh Source Type: research
Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia
CONCLUSIONS: These results highlight TIM-4-L as a highly prevalent target on AML across a range of genetic classifications and novel target for T cell-based therapy in AML. Further investigations into the role of TIM-4-L in AML pathogenesis and its potential as an anti-leukemic target for clinical development are warranted.PMID:38451195 | DOI:10.1158/1078-0432.CCR-23-3044 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 7, 2024 Category: Cancer & Oncology Authors: Brandon Cieniewicz Edson Oliveira Mike Saxton Damoun Torabi Ankit Bhatta Phanidhar Kukutla Alexander Arballo Zhuo Yang Bi Yu Maria Fate Hongxiu Ning Lawrence Corey Abhishek Maiti Daniel Corey Source Type: research
Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia
CONCLUSIONS: Our study demonstrates a compelling rationale for translating CCL2/CCR2 axis inhibitors in combination with MEK pathway-targeting therapies, as a potent strategy for combating drug resistance in AML. This approach has the potential to enhance the efficacy of treatments to improve AML patient outcomes.PMID:38451486 | DOI:10.1158/1078-0432.CCR-23-2654 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 7, 2024 Category: Cancer & Oncology Authors: Rucha V Modak Katia G de Oliveira Rebola John McClatchy Mona Mohammadhosseini Alisa Damnernsawad Stephen E Kurtz Christopher A Eide Guanming Wu Ted Laderas Tamilla Nechiporuk Marina A Gritsenko Joshua R Hansen Chelsea Hutchinson Sara J C Gosline Paul Pieh Source Type: research
Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma
CONCLUSIONS: Encorafenib and binimetinib exhibit positive tumor responses in patients with recurrent BRAF-V600E mutant HGG in this small series, warranting therapeutic consideration. Although toxicity remains a concern for BRAF-targeted therapies, no new safety signal was observed in these patients.PMID:38446982 | DOI:10.1158/1078-0432.CCR-23-3241 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 6, 2024 Category: Cancer & Oncology Authors: Karisa C Schreck Roy E Strowd Louis B Nabors Benjamin M Ellingson Michael Chang Sze K Tan Zied Abdullaev Rust Turakulov Kenneth Aldape Neeraja Danda Serena Desideri Joy Fisher Michaella Iacoboni Trisha Surakus Michelle A Rudek Chetan Bettegowda Stuart A G Source Type: research
A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
CONCLUSIONS: Trametinib was associated with reduction in EHE-related pain and median PFS of more than 6 months providing palliative benefit in patients with advanced EHE, but the trial did not meet the ORR goal.PMID:38446990 | DOI:10.1158/1078-0432.CCR-23-3817 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 6, 2024 Category: Cancer & Oncology Authors: Scott M Schuetze Karla V Ballman Rachel Heise Kristen N Ganjoo Elizabeth J Davis Suzanne George Melissa A Burgess Edwin Choy Dale R Shepard Gabriel Tinoco Angela Hirbe Ciara M Kelly Steven Attia Hari A Deshpande Gary K Schwartz Brittany L Siontis Richard Source Type: research
Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
CONCLUSIONS: These data highlight the role of immune cell regulation in the progression of CH to MN and the promise of leveraging multi-omic characterization of CH to improve MN risk stratification.PMID:38446993 | DOI:10.1158/1078-0432.CCR-23-3468 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 6, 2024 Category: Cancer & Oncology Authors: Duc Tran J Scott Beeler Jie Liu Brian Wiley Irenaeus C C Chan Zilan Xin Michael H Kramer Armel L Batchi-Bouyou Xiaoyu Zong Matthew J Walter Giulia E M Petrone Sarantis Chlamydas Francesca Ferraro Stephen T Oh Daniel C Link Ben Busby Yin Cao Kelly L Bolton Source Type: research
FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
Clin Cancer Res. 2024 Mar 5. doi: 10.1158/1078-0432.CCR-23-3738. Online ahead of print.ABSTRACTOn April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (EV) plus pembrolizumab for treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Substantial evidence of effectiveness was obtained from EV-103/KEYNOTE-869 (NCT03288545), a multi-cohort study. Across cohorts, a total of 121 patients received EV 1.25 mg/kg (maximum of 125 mg) intravenously on days 1 and 8 of a 21-day cycle plus pembrolizumab 200 mg intravenously on da...
Source: Clinical Cancer Research - March 5, 2024 Category: Cancer & Oncology Authors: William F Maguire Daniel Lee Chana Weinstock Xin Gao Catharine C Bulik Sundeep Agrawal Elaine Chang Salaheldin S Hamed Erik W Bloomquist Shenghui Tang Richard Pazdur Paul G Kluetz Laleh Amiri-Kordestani Daniel L Suzman Source Type: research
Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase 2 Randomised, Placebo-Controlled Trial
CONCLUSION: We could not confirm superiority of the ASC relative to placebo. ASC therapy significantly improved UWS in previous head and neck cancer patients, whereas placebo resulted in an insignificant increase.PMID:38441659 | DOI:10.1158/1078-0432.CCR-23-3675 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 5, 2024 Category: Cancer & Oncology Authors: Kathrine Jakobsen Amanda-Louise Fenger Carlander Tobias Todsen Jacob Melchiors Natasja Paaske Anne Kathrine Østergaard Madsen Simone Kloch Bendtsen Christine Mordhorst Helene Stampe Jens Kastrup Annette Ekblond Mandana Haack-S ørensen Mohammad Farhadi C Source Type: research
FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
Clin Cancer Res. 2024 Mar 5. doi: 10.1158/1078-0432.CCR-23-3738. Online ahead of print.ABSTRACTOn April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (EV) plus pembrolizumab for treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Substantial evidence of effectiveness was obtained from EV-103/KEYNOTE-869 (NCT03288545), a multi-cohort study. Across cohorts, a total of 121 patients received EV 1.25 mg/kg (maximum of 125 mg) intravenously on days 1 and 8 of a 21-day cycle plus pembrolizumab 200 mg intravenously on da...
Source: Clinical Cancer Research - March 5, 2024 Category: Cancer & Oncology Authors: William F Maguire Daniel Lee Chana Weinstock Xin Gao Catharine C Bulik Sundeep Agrawal Elaine Chang Salaheldin S Hamed Erik W Bloomquist Shenghui Tang Richard Pazdur Paul G Kluetz Laleh Amiri-Kordestani Daniel L Suzman Source Type: research
